GC Cell And Checkpoint Therapeutics To Explore Combined Therapeutic Potential Of Cosibelimab
Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC